MEDOZONAS - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 21,506 | 19,271 | 18,048 | 16,998 | 26,132 | 31,525 | 30,929 | 20,652 |
| Profit before tax | -691 | -1,631 | 4,380 | -1,337 | 3,670 | 568 | 2,052 | -3,986 |
| Net profit | -691 | -1,631 | 4,159 | -1,337 | 3,552 | 533 | 1,924 | -3,986 |
| Equity | 4,086 | 2,454 | 6,614 | 5,277 | 8,829 | 9,362 | 11,286 | 1,419 |
| Liabilities | 35 | 909 | 1,519 | 1,145 | 793 | 176 | 417 | 1,351 |
| Non-current assets | 2 | 803 | 1,051 | 1,538 | 827 | 335 | 71 | 1 |
| Current assets | 4,119 | 2,560 | 7,080 | 4,764 | 8,687 | 9,069 | 11,520 | 2,660 |
| Total assets | 4,121 | 3,363 | 8,131 | 6,302 | 9,514 | 9,404 | 11,591 | 2,661 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 1,535 | 1,482 | 2,198 |
| Social insurance contributions | - | - | - | - | - | 4,978 | 5,576 | 3,956 |
|
Financial indicators
|
||||||||
| Revenue change y/y | -13.4% | -10.4% | -6.3% | -5.8% | +53.7% | +20.6% | -1.9% | -33.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | -16.8% | -48.5% | 51.1% | -21.2% | 37.3% | 5.7% | 16.6% | -149.8% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | -16.9% | -66.5% | 62.9% | -25.3% | 40.2% | 5.7% | 17.0% | -280.9% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | -3.2% | -8.5% | 23.0% | -7.9% | 13.6% | 1.7% | 6.2% | -19.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | -3.2% | -8.5% | 24.3% | -7.9% | 14.0% | 1.8% | 6.6% | -19.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.0 | 0.4 | 0.2 | 0.2 | 0.1 | 0.0 | 0.0 | 1.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 4,576 | 5,139 | 4,512 | 4,146 | 6,533 | 7,881 | 7,732 | 4,859 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
MEDOZONAS - Social security debts
The amount of overdue SODRA debt for the company MEDOZONAS as of the last working day is: 0 €
| From | To | Debt, € |
|---|---|---|
| 2026-09-16 | 2026-09-16 | 0.01 |
| 2026-07-19 | 2026-07-20 | 245.54 |
| 2026-07-16 | 2026-07-17 | 245.54 |
| 2025-09-16 | 2025-09-18 | 0.46 |
| 2024-09-17 | 2024-09-18 | 464.29 |
| 2023-05-02 | 2023-05-09 | 1.55 |
| 2023-04-26 | 2023-04-28 | 1.55 |
| 2023-01-17 | 2023-01-31 | 368.40 |
| 2022-12-16 | 2023-01-16 | 0.13 |
| 2022-11-21 | 2022-12-05 | 0.13 |
| 2022-11-17 | 2022-11-18 | 0.13 |
| 2022-10-18 | 2022-11-09 | 0.13 |
| 2022-09-16 | 2022-10-06 | 0.13 |
| 2022-08-23 | 2022-09-14 | 0.13 |
| 2022-07-25 | 2022-08-15 | 0.13 |
| 2022-07-18 | 2022-07-24 | 0.02 |
| 2022-06-16 | 2022-07-14 | 0.02 |
| 2022-04-28 | 2022-06-14 | 0.02 |
| 2022-03-16 | 2022-03-16 | 35.83 |
| 2022-01-31 | 2022-02-14 | 2.38 |
| 2021-11-08 | 2021-11-14 | 29.86 |
| 2021-10-27 | 2021-11-07 | 320.67 |
| 2021-10-18 | 2021-10-26 | 332.45 |
| 2021-09-16 | 2021-10-14 | 0.25 |
MEDOZONAS - VMI tax arrears
As of 2026-09-14, the amount of overdue STI tax debt of the company MEDOZONAS is: 1 €
| From | To | Overdue, € |
|---|---|---|
| 2026-08-28 | 2026-09-14 | 0.67 |
| 2026-08-13 | 2026-08-27 | 45.11 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
MEDOZONAS, UAB is a Private Limited Liability Company (code 301486775) operating in medical specialists activities. In 2025, the company generated revenue of €20.7K, down 33.2% year on year and 34.5% over two years. Net profit turned to a loss of €4.0K, compared with €1.9K profit in 2024 and €533 in 2023, showing a clear weakening in profitability. The 2025 profit margin was -19.3%. Balance sheet scale also contracted materially: total assets fell to €2.7K from €11.6K a year earlier, while equity decreased to €1.4K and liabilities were €1.4K. Short-term assets accounted for nearly all assets, with long-term assets of only €1. The company’s equity ratio was 53.3% and debt-to-equity stood at 0.95, while asset turnover was 7.76x. Revenue per employee was €5.2K and profit per employee was -€996, indicating modest operating scale and weaker performance in the latest financial year.